ACCESS Newswire
20 May 2020, 17:01 GMT+10
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointments of David R. Epstein and C. David Nicholson, PhD, to its Board of Directors, effective May 14, 2020.
David Epstein is executive partner at Flagship Pioneering and Chairman of Axcella Health, Rubius Therapeutics and Evelo Biosciences. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis' Oncology and Molecular Diagnostic units. Under his leadership, the company's oncology business grew to the second largest in the world.
David has more than 25 years of extensive drug development, deal-making, commercialization and leadership experience on a global scale. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec®, Tasigna®, Gilenya®, Cosentyx® and Entresto®. His teams developed three Prix Galien award winners and he has developed and steered several successful executive teams. David was named by FierceBiotech as one of the '25 most influential people in biopharma.'
'I am most impressed with the potential of Tarus's adenosine antagonist compounds to be proven to be best in class,' said David Epstein. 'I look forward to the filing of these near term INDs and the start of clinical programs.'
Dr. Nicholson has over forty years of experience in research and development in the pharmaceutical industry spanning senior leadership roles at Allergan, Bayer CropScience, Schering-Plough, Organon and Merck. David was Chief R&D Officer at Allergan prior to its acquisition by AbbVie in May 2020, and also serves on the Board of Directors of Science Exchange and Actinium Pharmaceuticals. Dr. Nicholson joined Allergan (then Actavis) in August 2014 as Senior Vice President, Global Brands R&D. Previously he was on the Executive Committee of Bayer CropScience as Head of R&D responsible for the integration of the company's activities into one global organization.
Dr. Nicholson also worked with Beecham-Wülfing, Germany, and held various senior positions at Organon, a Business Unit of Akzo Nobel, where he was Executive Vice President, Research & Development, and member of the Organon Executive Management Committee. David played a significant role in the strategic merger of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007, as well as the merger of Schering-Plough and Merck in 2009.
'I am delighted to join the Board of Tarus Therapeutics,' said Dr Nicholson. 'And look forward to seeing the full potential of their range of adenosine receptor antagonists being developed.'
'We are very pleased to welcome David Epstein and David Nicholson, with their highly distinguished careers in the life sciences industry, to our Board of Directors', added Sushant Kumar, PhD, President and CEO of Tarus Therapeutics, Inc. 'We look forward to their valuable contributions as we advance the Company's adenosine receptor antagonist programs towards clinical trials for cancer immunotherapy and other select non-oncology indications.'
About Tarus Therapeutics Inc.
Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.
Contact:
Tarus Therapeutics, Inc.
Peter Molloy
Co-Founder & Executive Director
[email protected]
SOURCE: Tarus Therapeutics via EQS Newswire
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationSEATTLE, Washington: Nordstrom delivered stronger-than-expected holiday-quarter sales and announced a leadership shakeup, with Chief...
MILAN, Italy: Prada CEO Andrea Guerra suggested this week that the Italian luxury brand is keeping its options open regarding potential...
OSLO/COPENHAGEN: Tesla is experiencing a sharp drop in sales across Scandinavia and France as shifting consumer sentiment and an aging...
NEW YORK, New York - U.S. stocks fell sharply Thursday as investors and traders struggled with Presient Trump's controversial trade...
TOKYO, Japan: Honda is making a strategic shift in its production plans, moving the next-generation Civic hybrid manufacturing from...
CINCINNATI, Ohio: Kroger CEO Rodney McMullen has resigned following a board investigation that found his personal conduct to be inconsistent...
CNN - In a recent interview with CNN's Christiane Amanpour, Canadian Foreign Minister Mélanie Joly expressed strong opposition to President...
CAPE CANAVERAL, Florida: This week, a small NASA satellite was launched into space from Florida to find and map water on the moon....
DES MOINES, Iowa: Iowa lawmakers have passed a new law that removes protections for gender identity from the state's civil rights code....
(Photo credit: Isaiah J. Downing-Imagn Images) Cale Makar produced two goals and four assists for the first six-point game of his...
(Photo credit: James Guillory-Imagn Images) Seth Jarvis scored with 18.6 seconds remaining, lifting the Carolina Hurricanes to a...
(Photo credit: Nathan Ray Seebeck-Imagn Images) Luka Doncic scored five of his 32 points in overtime, LeBron James added 31 points...